Economic evaluation of assistance to HIV patients in a Spanish hospital

European Journal of Internal Medicine

Volumn 18, Issue 5, 2007, Pages 400-404

  Velasco, M ^a   Losa, J E ^a   Espinosa, A ^a   Sanz, J ^b   Gaspar, G ^c   Cervero, M ^d   Torres, R ^d   Condes, E ^e   Barros, C ^e   Castilla, V ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

Costs; Economics; Health care; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AMBULATORY SURGERY; ARTICLE; COST CONTROL; DAY CARE; DIAGNOSIS RELATED GROUP; DRUG COST; ECONOMIC EVALUATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTPATIENT CARE; SPAIN;

EID: 34547686112     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.12.013     Document Type: Article

References (16)

1. Yazdanpanah Y., Goldie S.J., Losina E., Weinstein M.C., Lebrun T., Paltiel A.D., et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 7 4 (2002) 257-266
2. Walensky R., et al. 12th Conference on Retroviruses and Opportunistic Infections. Boston. February (2005) [Abstract 143LB]
3. Velasco M., Gomez A., Fernandez C., Perez-Cecilia E., Tellez M.J., Roca V., et al. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. HIV Med 1 4 (2000) 246-251
4. Cook J., Dasbach E., Coplan P., Markson L., Yin D., Meibohm A., et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retrovir 15 6 (1999) 499-508
5. Freedberg K.A., Losina E., Weinstein M.C., Paltiel A.D., Cohen C.J., Seage G.R., et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344 11 (2001) 824-831
6. Sendi P., Palmer A.J., Gafni A., and Battegay M. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. PharmacoEconomics 19 7 (2001) 709-713
7. Krentz H., Auld C., Gill J., and for the HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 169 2 (2003) 106-110
8. Bozzette S.A., Joyce G., McCaffrey D.F., Leibowitz A.A., Morton S.C., Berry S.H., et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 344 11 (2001) 817-823
9. Gebo K.A., Chaisson R.E., Folkemer J.G., Bartlett J.G., and Moore R.D. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 13 8 (1999) 963-969
10. Mouton Y., Alfandari S., Valette M., Cartier F., Dellamonica P., Humbert G., et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 11 12 (1997) F101-F105
11. Stoll M., Claes C., Schulte E., Graf von der Schulenburg J.M., and Schmidt R.E. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res 7 11 (2002) 463-471
12. Torti C., Casari S., Palvarini L., Quiros-Roldan E., Moretti F., Leone L., et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy 65 3 (2003) 261-267
13. Le Pen C., Rozenbaum W., Downs A., Maurel F., Lilliu H., and Brun C. Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach. HIV Clin Trials 2 2 (2001) 136-145
14. Rodriguez-Vidigal F.F., and Habernau A. Cause of hospitalization in patients with human immunodeficiency virus infection in a rural area. Role of chronic liver disease. Enferm Infecc Microbiol Clin 22 3 (2004) 138-141
15. Jaen A., Casabona J., Esteve A., Miro J.M., Tural C., Ferrer E., et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project. Med Clin (Barc ) 124 14 (2005) 525-531
16. Beck E.J., Mandalia S., Gaudreault M., Brewer C., Zowall H., Gilmore N., et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 18 18 (2004) 2411-2418